Introduction {#Sec1}
============

Depressive disorders are amongst the leading causes of disability and mortality worldwide and account for more years lived with disease than any other illness (Beddington et al. [@CR3]; Murray and Lopez [@CR36]). Furthermore, the majority of depressed individuals relapse (Mueller et al. [@CR35]), and with each successive episode, the rate of subsequent recurrence increases (Kessing et al. [@CR29]) such that life for most sufferers becomes a chronic cycle of illness and recovery.

The monoamine serotonin (5-HT) is thought to play a role in major depression (Owens and Nemeroff [@CR42], but see Lacasse and Leo [@CR30] for an alternative view). Specifically, patients with depression show reduced serotonin levels (Cowen et al. [@CR13]; Placidi et al. [@CR45]), abnormal serotonin receptor function (Drevets et al. [@CR17]; Ellis and Salmond [@CR19]) and abnormal serotonin transporter function (Caspi et al. [@CR9]; Heils et al. [@CR26]; Lesch et al. [@CR31]). Moreover, elevation of serotonin via selective serotenergic reuptake inhibitors can reduce the symptoms of depression (Harmer [@CR25]).

One way to manipulate serotonin in healthy individuals is via the dietary manipulation of the serotonin precursor tryptophan (acute tryptophan depletion; ATD). This manipulation is thought to significantly reduce central 5-HT levels (Ardis et al. [@CR2]; Reilly et al. [@CR47]) and can provoke some of the cognitive effects seen in depressed individuals in healthy individuals (e.g. Evers et al. [@CR20]; Murphy et al. [@CR37]; Sambeth et al. [@CR57]). However, ATD has no reliable effects upon the mood state of healthy individuals (Robinson and Sahakian [@CR51]; Ruhe et al. [@CR56]). In individuals who have recovered from depression, on the other hand, ATD can induce significant negative mood (Delgado et al. [@CR15]; Smith et al. [@CR60]), particularly in those who were successfully treated with SSRIs (and therefore presumably had reduced 5-HT) during their first episode (Booij et al. [@CR5]; Van der Does [@CR63]). An important unresolved question, therefore, is why a discrepancy exists between the effects of ATD on mood state in never- and recovered-depressed individuals.

To explain this phenomenon, we have previously proposed a hypothetical neurocognitive mechanism by which mood state and reduced serotonin may become linked during an episode of depression (Robinson and Sahakian [@CR50]). The central tenet of this hypothesis is that associative learning (Dickinson [@CR16]) causes a link to be formed between the neural substrates implicated in negative mood and the neural substrates implicated in a reduced serotonin state during their depression-linked co-occurrence. Such an association would mean that re-evocation of one state would trigger the other. In other words, a permanent association between negative mood and a low serotonin in depressed individuals would result in negative mood following an ATD-induced low serotonin state. Individuals who have never suffered from depression, on the other hand, are not likely to have previously experienced concurrent reduced serotonin and negative mood, will not have such an association and will not therefore experience ATD evoked negative mood. The term 'kindling' has previously been used to describe the changes that occur during an episode of depression, which promote the onset of future episodes (Kendler et al. [@CR28]; Post and Weiss [@CR46]; Segal et al. [@CR58]). A link between low serotonin and negative mood may therefore underlie such a kindling effect.

In order to test this hypothesis, we attempted to artificially associate negative mood with a reduced a serotonin state in healthy individuals. Mood state was manipulated via an established mood induction procedure (MIP; Robinson et al. [@CR52]; Robinson and Sahakian [@CR51]) and serotonin was manipulated via ATD. Four separate groups were tested on two occasions separated by at least a week. In the main group of interest, subjects received ATD and negative MIP on their first visit but ATD and neutral MIP on their second visit. Another group received ATD on both visits but neutral MIP on both the first and second visit. Two matched control groups received either neutral or negative MIP on their first visit but received a balanced amino-acid drink instead of ATD on both visits. Both control groups also received neutral MIP on their second visit. If our hypothesis is correct, then ATD will have no effect upon mood on the first visit (in all groups) but evoke negative mood on the second visit of the group who received both ATD and negative MIP on their first visit.

This study therefore tested the hypothesis that associations can form between reduced serotonin state and negative mood.

Methods {#Sec2}
=======

Procedures were approved by the Cambridge Research Ethical Committee (06/Q0108/160) and were in accord with the Helsinki Declaration of 1975. Depression is more common in females than males (Kendler et al. [@CR27]), and previous research has demonstrated that ATD has increased effects in females relative to males (Ellenbogen et al. [@CR18]; Robinson et al. [@CR52]; Sambeth et al. [@CR57]) so recruitment was restricted to females. Forty-two subjects were recruited. One subject failed to complete either testing session. The remaining 41 subjects were then divided into four groups: (1) ATD subjects who underwent neutral MIP on visit 1 (*N* = 11), (2) ATD subjects who underwent negative MIP on visit 1 (*N* = 10), (3) BAL subjects who underwent neutral MIP on visit 1 (*N* = 10), (4) BAL subjects who underwent negative MIP on visit 1 (*N* = 10). All subjects received neutral MIP on visit 2. Thirty-eight subjects completed a second session (group 1 *N* = 10; group 2, *N* = 8; group 3 *N* = 10; group 4 *N* = 10; Table [1](#Tab1){ref-type="table"}). All subjects were screened for psychiatric and neurological disorders, gave written informed consent and were compensated for participation. Exclusion criteria were cardiac, hepatic, renal, pulmonary, neurological, psychiatric or gastrointestinal disorders, drug use and personal or family history of any depressive disorder. The mean age of subjects was \[years\] 28 (SD = 6). Subjects were tested on two sessions, separated by at least 1 week. They were instructed to abstain from alcohol, caffeine and food from midnight prior to each session. Table 1Group descriptionGroupVisit 1Visit 21ATDNEUT MIPATDNEUT MIP2ATDNEG MIPATDNEUT MIP3BALNEUT MIPBALNEUT MIP4BALNEG MIPBALNEUT MIP

Protocol {#Sec3}
--------

Subjects arrived at the research centre between 08:30 and 10:30 and consumed the amino-acid mixture. At *T*~0~, a blood sample was taken, and a nutritionally balanced (BAL) or a tryptophan free (ATD) amino-acid drink was ingested. Following this, they were allowed to consume water and were given a low protein snack (an apple) for lunch. After a resting period of approximately 5 h to ensure stable and low tryptophan levels (Carpenter et al. [@CR8]), a second blood sample was taken (*T*~1~), and the mood induction procedure was completed.

Amino-acid mixtures {#Sec4}
-------------------

Amino-acid mixtures (prepared by SHS international; Liverpool, UK) were identical to previous research (Cools et al. [@CR11]; Robinson et al. [@CR52]; Robinson and Sahakian [@CR51]; Roiser et al. [@CR53]): [l]{.smallcaps}-alanine, 2.9 g; [l]{.smallcaps}-arginine, 2.6 g; [l]{.smallcaps}-cystine, 1.4 g; glycine, 1.7 g; [l]{.smallcaps}-histidine, 1.7 g; [l]{.smallcaps}-isoleucine, 4.2 g; [l]{.smallcaps}-leucine, 7.1 g; [l]{.smallcaps}-lysine, 4.7 g; [l]{.smallcaps}-methionine, 1.6 g; [l]{.smallcaps}-proline, 6.4 g; [l]{.smallcaps}-phenylalanine, 3.0 g; [l]{.smallcaps}-serine, 3.6 g; [l]{.smallcaps}-threonine, 3.4 g; [l]{.smallcaps}-tyrosine, 3.6 g; [l]{.smallcaps}-valine, 4.7 g; [l]{.smallcaps}-tryptophan, 2.1 g---total BAL, 54.7/TRP, 52.6 g. The drinks were prepared by stirring the mixture into approximately 200 ml tap water with either lemon-lime or grapefruit flavouring. Subjects reported no side effects apart from transient nausea following ingestion of the drink.

Blood (venous) samples (10 ml) were taken immediately before ingestion of the amino-acid drink (*T*~0~) and approximately 5 h after administration (*T*~1~) to determine the crucial TRP/sum of the long neutral amino acids (ΣLNAA) ratio.

Mood induction procedure {#Sec5}
------------------------

The MIP has been comprehensively described elsewhere (Robinson et al. [@CR52]; Robinson and Sahakian [@CR51]). Subjects were asked to relate negative or neutral Velten sentences to situations in their own lives whilst listening to mood-congruent music. It was programmed in Microsoft Visual Basic 6 (Microsoft Corporation, Redmond, WA, USA) and presented on a Paceblade tablet computer (11-in. monitor). A set of visual analogue scales (VAS) was administered at *T*~0~ (admission), *T*~1~ (5 h later pre-MIP) and *T*~2~ (post-MIP) to determine self-reported mood.

Results {#Sec6}
=======

Amino-acid mixtures {#Sec7}
-------------------

Incomplete amino-acid data (Table [2](#Tab2){ref-type="table"}) were available for ten participants due to blood extraction problems, but it should be noted that the same amino-acid mixture (made by the same manufacturer) was successfully used in three previous studies (Cools et al. [@CR12]; Robinson et al. [@CR52]; Robinson and Sahakian [@CR51]). A repeated-measures ANOVA revealed a significant two-way drink × time interaction for the critical TRP/ΣLNAA ratio (treatment × time: *F*~1~,~29~ = 59, *P* \< 0.001). Table 2Biochemical measuresBALATD*T*~1~*T*~2~*T*~1~*T*~2~TRP (nmol/ml)34(3.3)108(10)34(3.2)10(9.8)TRP/ΣLNAA0.11(0.01)0.18(0.02)0.12(0.01)0.01(0.02)Values represent mean (standard error of the mean)

Simple effects analysis revealed that the significant drink × time interaction was due to a 92% decrease in the TRP/ΣLNAA ratio between *T*~0~ and *T*~1~ following ATD (significant effect of time: *F*~1,29~ = 44.7, *P* \< 0.001) and a 64% increase in the TRP/ΣLNAA ratio between *T*~0~ and *T*~1~ following BAL (*F*~1,29~ = 18.5, *P* \< 0.001).

A similar pattern was seen in the TRP levels on their own (treatment × time: *F*~1~,~29~ = 56, *P* \< 0.001; significant effect of time under ATD: *F*~1,29~ = 6.9, *P* = 0.013 and BAL: *F*~1,29~ = 61, *P* \< 0.000).

Mood state {#Sec8}
----------

Incomplete VAS scales were available for the first visit of four subjects (one per group) and for the second visit of two subjects (one in group 1, one in group 4).

### Visit 1 {#Sec9}

There were no treatment by time (*F*~1,33~ = 0.046, *P* = 0.83), time by MIP (*F*~1,33~ = 0.13, *P* = 0.73) or treatment by time by MIP interactions (*F*~1,33~ = 0.50, *P* = 0.48) between *T*~0~ and *T*~1~ on the Sad VAS subscale. The same absence of an effect was seen on the happy VAS (no effect of treatment × time, *F*~1,33~ = 0.68, *P* = 0.42; time × MIP, *F*~1,33~ = 1.6, *P* = 0.22; or treatment × time × MIP interaction *F*~1,33~ = 0.51, *P* = 0.48). This indicates that the drink itself did not change subjects\' mood and that this did not differ between groups.

However, there was an effect of time between *T*~1~ and *T*~2~ before and after the MIP on the sad VAS (*F*~1,34~ = 9.7, *P* = 0.004) and although there was no time by MIP (*F*~1,34~ = 2.2, *P* = 0.15) interaction or time by MIP by treatment interaction (*F*~1,34~ = 0.076, *P* = 0.79), when stratified by group, there was a significant increase in sad ratings in the negative (main effect of time; *F*~1,34~ = 9.9, *P* = 0.003) but not neutral mood group (no effect of time; *F*~1,34~ = 1.44, *P* = 0.24). There was also an effect of time (*F*~1,34~ = 5.3, *P* = 0.027) and a non-significant trend towards a time by mood interaction on the happy VAS (*F*~1,33~ = 3.4, *P* = 0.074) which was again, when stratified by group, driven by a significant reduction in happy ratings (main effect of time; *F*~1,33~ = 8.2, *P* = 0.007) in the negative but not neutral MIP (no effect of time; *F*~1,33~ = 0.11, *P* = 0.74) group. Thus, the negative MIP increased sad and decreased happy ratings, whereas the neutral MIP had no effect on either rating. Thus, although there was no significant main effect, there was a non-significant trend in the 'happy' ratings, and the simple effects were significant in both happy and 'sad' ratings. As such, we argue that---consistent with previous studies utilising the same technique (Robinson [@CR48]; Robinson et al. [@CR52]; Robinson and Sahakian [@CR51])---the MIP was successful. The alternative assumption (that the MIP was unsuccessful) cannot account for the significant findings on the second visit. The lack of a main effect may be due to reduced statistical power resulting from a non-optimal sample size.

### Visit 2 {#Sec10}

There was a significant interaction between time, treatment and MIP between *T*~0~ and *T*~1~ on the sad VAS (*F*~1,32~ = 8.0, *P* = 0.008). This was driven by a significant lowering of mood in the subjects in group 2 (who underwent both negative MIP and ATD on the first visit: main effect of time *F*~1,32~ = 14, *P* = 0.001) but no change in the moods of groups 1 (no effect of time *F*~1,32~ = 0.077, *P* = 0.78), 3 (no effect of time *F*~1,32~ = 0.11, *P* = 0.74) or 4 (no effect of time *F*~1,32~ = 1.3, *P* = 0.25). There was no such interaction on the happy VAS (no time × treatment × mood interaction: *F*~1,32~ = 0.034, *P* = 0.85). Thus, ATD evoked negative mood *but only* in those subjects who received both negative MIP and ATD on their first visit (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}). Fig. 1Mean difference in the self-report visual analogue scale 'How sad are you?' between *T*~0~ and *T*~1~ in subjects undergoing ATD. ATD-induced significant negative mood on visit 2 of those subjects who received ATD and negative MIP during visit 1 (\**P* = 0.001, *NS* not significant)Fig. 2Mean difference in the self-report visual analogue scale 'How sad are you?' between *T*~0~ and *T*~1~ in subjects undergoing BAL. No changes in mood were seen (*NS* not significant)

There was also an interaction between time, treatment and MIP before (*T*~1~) and after (*T*~2~) the neutral MIP on the sad VAS (*F*~1,32~ = 5.6, *P* = 0.024). This was due to a significant reduction in sad ratings following the MIP in group 2 (main effect of time *F*~1,32~ = 9.8, *P* = 0.004) but no change in the moods of groups 1 (no effect of time *F*~1,32~ = 1.6, *P* = 0.22), 3 (no effect of time *F*~1,32~ = 0.37, *P* = 0.55) or 4 (no effect of time *F*~1,32~ = 0.6, *P* = 0.46). There was no such interaction on the happy VAS (no time × treatment × mood interaction: *F*~1,32~, \< 0.000, *P* = 0.98). Thus, the neutral MIP actually served to neutralise the negative mood state induced by ATD in group 2.

It should be noted that the effect of interest is only revealed when time is included as a within subjects factor. There is no significant difference between the sad ratings of each group at each time point (Table [3](#Tab3){ref-type="table"}). In other words, there is a significant within- but not between-subjects change in mood state. This indicates that although a combination of ATD and mood induction on the first visit caused a significant *change* in mood state on a second visit, this change nevertheless remains within the boundaries of 'normal' sad mood ratings. Table 3Visual analogue ratingsGroup*T*~0~*T*~1~*T*~2~Visit 11(*N* = 10)1.32(0.71)1.52(0.62)2.06(0.77)2(*N* = 9)0.41(0.82)0.94(0.70)3.43(0.91)3(*N* = 9)1.53(0.72)2.57(0.62)3.2(0.80)4(*N* = 9)2.67(0.71)2.86(0.62)4.29(0.77)ANOVA*F*~3,33~ = 1.5, *P* = 0.24*F*~3,34~ = 0.6, *P* = 0.62*F*~3,35~ = 0.83, *P* = 0.49Visit 21(*N* = 9)2.21(0.74)2.03(0.74)2.66(0.76)2(*N* = 8)0.64(0.87)2.9(0.87)1.27(0.89)3(*N* = 10)2.96(0.76)2.93(0.77)3.6(0.79)4(*N* = 9)2.42(0.74)1.68(0.74)2.06(0.76)ANOVA*F*~3,33~ = 1.7, *P* = 0.19*F*~3,32~ = 1.1, *P* = 0.36*F*~3,32~ = 1.09, *P* = 0.37Values represent the visual analogue response to the question 'How sad are you?' (cm). ANOVAs reveal all four groups to be matched at all time points

Discussion {#Sec11}
==========

Tryptophan depletion had no effect upon the mood state of healthy females on their first visit. However, those who received negative mood induction following tryptophan depletion during their first visit experienced a significant lowering of mood following tryptophan depletion on their second visit. This effect was not seen in those who experienced a neutral mood induction and tryptophan depletion on their first visit or in those who received a balanced placebo and negative mood induction on their first visit. This finding therefore provides preliminary experimental data to support the associative hypothesis of recurrence in depression (Robinson and Sahakian [@CR50]) and may therefore explain the discrepancies between the effects of tryptophan depletion in never- and recovered- depressed individuals (Booij et al. [@CR4]).

The first important finding, therefore, is that there was no significant change in mood between *T*~0~ and *T*~1~ on the first visit of all four groups. This supports the hypothesis that tryptophan depletion does not, in itself, cause negative mood. Although this is inconsistent with early reports (Young et al. [@CR66], [@CR65]), more recent studies have failed to replicate these findings (Booij et al. [@CR5], [@CR4]), and it is now thought that any link between 5-HT and mood is likely to be indirect (Robinson and Sahakian [@CR51]; Ruhe et al. [@CR56]). Moreover, the present data demonstrate that ATD does not necessarily induce negative mood in healthy *females*, despite the suggestion that female gender might be a risk factor for mood response to ATD (Booij et al. [@CR4]). Thus, this finding supports the hypothesis that ATD does not induce negative mood state in healthy individuals who have never suffered from (and are not predisposed to) depression.

The observation that tryptophan depletion *did* induce negative mood on the second visit of those who received both negative mood and ATD on their first visit then supports the associative hypothesis of recurrence in depression (Robinson and Sahakian [@CR50]). Negative mood and reduced serotonin frequently co-occur in depression (APA [@CR1]; Owens and Nemeroff [@CR42]), and ATD provokes significant negative mood in subjects who have previously suffered from depression (Booij et al. [@CR4]). The present findings therefore suggest that ATD may provoke negative mood in (at least some) recovered depressed individuals because both negative mood and reduced serotonin co-occurred during their first episode of depression.

An important question, therefore, is why previous co-occurrence of negative mood and low serotonin would cause ATD to become linked with negative mood. A number of theories which are relevant to this phenomenon have been highlighted (Robinson and Sahakian [@CR50]). The most important of these is associative learning theory, which describes how two events (in this case, negative mood and reduced serotonin) can become linked by occurring at the same time (Dickinson [@CR16]). Future occurrence of one event then re-evokes the other. Such learning is thought to be underpinned at the neural level by Hebbian learning (Paulsen and Sejnowski [@CR44]) in which 'cells that fire together, wire together'. If both the negative mood and reduced serotonin states evoke dissociable patterns of neural activity, then these patterns of neural activity may 'wire together' when they co-occur during an episode of depression (or, indeed, in the artificial situation in the present study). In particular, mood states are associated with activity in prefrontal cortical regions (Garrett and Maddock [@CR22]; Habel et al. [@CR24]; Mayberg et al. [@CR33]; Mitchell and Phillips [@CR34]; Taylor Tavares et al. [@CR61]), whereas serotonin influences a diverse range of cortical and subcortical regions (Cools et al. [@CR10]; Harmer [@CR25]; Roiser et al. [@CR54]; van der Veen et al. [@CR64]). Thus, the neurons responsible for the prefrontal activations associated with negative mood may wire together with the distinct cortico-subcortical pattern associated with the reduced serotonin state. This is redolent of the 'as-if body' loop outlined by Damasio ([@CR14]), which postulates that the neural substrates associated with moods can be independently evoked in the absence of the somatic changes, which may have originally triggered the state.

It should be noted that the restriction of this finding to group 2 indicates that the negative mood state is *specifically* associated with the reduced 5-HT state. The absence of the effect in group 4 indicates that negative mood cannot be associated with a more general state such as altered amino-acid levels or discomfort caused by the drink and/or the long waiting period. In other words, this effect is not driven by a *general* state-dependent recall of mood. The reduced 5-HT may therefore provoke increased activation in specific brain regions (e.g. the striatum Roiser et al. [@CR54]), which may then became associated with the neural substrates specific to the negative mood state (e.g. regions of the PFC (Gray et al. [@CR23]; Robinson and Sahakian [@CR51])). However, this associative hypothesis is clearly speculative, and the next step will be to use functional neuroimaging to examine the neural substrates underlying these preliminary behavioural observations.

This study may also have important implications for our understanding of relapse in depression. Following a first episode, subsequent episodes become increasingly likely (Kendler et al. [@CR28]), and these episodes become increasingly debilitating (Bouhuys and Sam [@CR6]; Fossati et al. [@CR21]; Nandrino et al. [@CR39]; Nandrino et al. [@CR38]; Sher et al. [@CR59]; Thase et al. [@CR62]) and increasingly easy to trigger (Lewinsohn et al. [@CR32]). The concept of 'kindling' has been proposed to explain this pattern (Kendler et al. [@CR28]; Post and Weiss [@CR46]; Segal et al. [@CR58]). In particular, it has been suggested that permanent changes might occur during a first episode of depression, which may make subsequent episodes more likely. The present data highlight the possibility that a permanent neural association between reduced serotonin and negative mood, formed during an episode of depression, may underlie this kindling effect. Such an association may mean that subsequent fluctuations in serotonin levels are more likely to trigger depressed mood and hence instigate a 'downwards spiral' into depression. Such associations could also be partially responsible for the cognitive impairment which can appear in remission in recovered depressed individuals (Paradiso et al. [@CR43]).

These findings therefore highlight the importance of treating not only the initial symptoms of depression but also any underlying kindling. Specifically, it may be important to attempt to break these proposed associations after an episode of depression has been successfully treated. Associative learning theory suggests that new associations are formed *over the top of* old associations rather than old associations being 'un-learned' (Bouton [@CR7]). Thus, one potential method of treating associations might be to attempt to associate reduced serotonin with a positive mood state in recovered depressed individuals. The observation that the neutral mood induction *improved* the ATD induced negative mood in the present study indicates that this may be possible. Recovered depressed individuals could therefore be tryptophan-depleted and then subjected to positive MIP (Robinson et al. [@CR52]; Robinson and Sahakian [@CR49]; Robinson and Sahakian [@CR51]; Roiser et al. [@CR55]) or behavioural therapy to elevate mood. If the associative hypothesis is correct, then an association may form between the low serotonin state and the positive mood state. As such, future fluctuations in 5-HT level should evoke positive rather than negative mood and thereby act as a buffer against the onset of depression. Nevertheless, this hypothesis is clearly speculative and requires further research.

It should be noted that whilst this hypothesis explains a number of previously observed discrepancies, it does not cover all eventualities. For instance, ATD has actually been shown to induce negative mood in healthy individuals who are at risk of depression (Booij et al. [@CR5]; Booij et al. [@CR4]; Neumeister et al. [@CR40]; Ruhe et al. [@CR56]). As such individuals have never suffered from an episode of depression the proposed hypothesis cannot explain their responses. It could be argued that their susceptibility to depression is provoked by the pre-existence of the proposed 5-HT and mood associations or that their susceptibility means that they are likely to have experienced sub-clinical episodes of negative mood and reduced serotonin, but these arguments are clearly speculative. Similarly, it should be noted that depression is a multi-faceted disorder and that not all sufferers experience reduced serotonin. Prior exposure to SSRIs has been shown to be a predictor of mood response following ATD (Booij et al. [@CR4]), so it is plausible that ATD-induced negative mood is only found in subjects whose depression was associated with reduced 5-HT, but this is also clearly speculative. It should therefore be emphasised that the proposed hypothesis is only really applicable to individuals who have experienced an episode of depression and who experienced reduced 5-HT during that episode.

As a further caveat, it should be noted that self report is an imperfect method of measuring mood state because it can be heavily reliant upon demand characteristics (Orne [@CR41]). This is particularly likely to be an issue with self-reported mood following mood induction as the desired mood state is likely to be fairly obvious to the volunteer. However, it should be noted that the effect of interest in the present findings was on the second visit *prior* to the MIP. Thus, at *T*~1~ on the second visit, the experiences of all groups were closely matched. An alternative demand characteristic may be that those who experienced negative MIP on the first visit would expect a negative MIP on the second visit. They may therefore report *anticipatory* negative mood just prior to the MIP. However, if this were the case, then self-reported negative mood would also be expected in the BAL group who experienced negative MIP on their first visit. The restriction of the finding to the one group suggests that the effect is indeed specific to those who experienced both negative MIP *and* ATD on the first visit. It should also be noted that one-way ANOVAs revealed no significant differences between the ratings of each group at each time point (see Table [3](#Tab3){ref-type="table"}). This means that none of the groups had abnormally low or high baseline mood ratings. As such, the ratings stayed within normal mood state, and significant effects were driven by significant within-subject *changes* in mood state rather than between-subject differences in mood state. As a further caveat, the sample size is fairly small, and so these data should be considered preliminary until they are replicated in a larger sample of subjects. In fact, the reduced statistical power associated with this sample size may underlie the lack of an interaction between MIP and time on the state ratings on the first visit. Nevertheless, the fact that the findings support a previously proposed hypothesis is promising.

Conclusion {#Sec12}
==========

In summary, these data provide preliminary support for the associative hypothesis of recurrence in depression. Reduced serotonin can evoke negative mood in healthy individuals but *only* in those who have previously experienced concurrent negative mood and reduced serotonin. It is hypothesised that this is because Hebbian associations form between the neural substrates of mood and 5-HT during their co-occurrence. As both reduced serotonin and negative mood are seen in depression, this may also explain why serotonin reduction can reliably induce negative mood in subjects who have recovered from depression but has no effect upon the moods of healthy individuals. These associations may therefore underlie, at least in part, the kindling effect in which an episode of depression makes subsequent episodes increasingly likely. As depression is a costly and growing problem, future research should therefore examine the neural basis of, and the possibility of breaking, these putative associations, thereby reducing recurrence in depression. The next step, however, is to replicate these preliminary findings in a larger sample of subjects.
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